Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
July 30, 2025 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
June 10, 2025 16:58 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)

NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory diseases,...
April 30, 2025 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
April 28, 2025 07:00 ET | Source: Lungpacer Medical USA Inc.

Lungpacer to Showcase the Potential of Novel Technologies to Improve Lung, Heart, and Brain Health in Ventilated Patients

This spring, Lungpacer Medical clinical experts and device innovators will be featured presenters at top industry events.
April 28, 2025 07:00 ET | Source: AccuStem Sciences, Inc.

AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening

LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk...
April 16, 2025 07:00 ET | Source: AccuStem Sciences, Inc.

AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan

LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of...
April 04, 2025 07:00 ET | Source: AccuStem Sciences, Inc.

AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States

LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of...
April 02, 2025 00:01 ET | Source: Curium

Curium Announces Approval of Generic DTPA - Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.

ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m...
March 18, 2025 08:30 ET | Source: AccuStem Sciences, Inc.

AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test

AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:...